Procter & Gamble Health Limited Asset Resilience Ratio
Procter & Gamble Health Limited asset resilience ratio. Procter & Gamble Health Limited (PGHL) has an Asset Resilience Ratio of 33.01% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PGHL defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Procter & Gamble Health Limited (2003–2024)
Asset resilience ratio of Procter & Gamble Health Limited from 2003 to 2024. This chart shows how Procter & Gamble Health Limited's Asset Resilience Ratio has changed over time. Read Procter & Gamble Health Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Procter & Gamble Health Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Procter & Gamble Health Limited's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs2.79 Billion | 31.23% |
| Short-term Investments | Rs159.40 Million | 1.78% |
| Total Liquid Assets | Rs2.95 Billion | 33.01% |
Asset Resilience Insights
- Very High Liquidity: Procter & Gamble Health Limited maintains exceptional liquid asset reserves at 33.01% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Procter & Gamble Health Limited Industry Peers by Asset Resilience Ratio
Compare Procter & Gamble Health Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Procter & Gamble Health Limited Asset Resilience Ratio by Year (2003–2024)
Procter & Gamble Health Limited asset resilience ratio by year from 2003 to 2024. The table below shows the annual Asset Resilience Ratio data for Procter & Gamble Health Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.33% | Rs1.14 Billion ≈ $12.31 Million |
Rs7.94 Billion ≈ $85.89 Million |
-6.95pp |
| 2023-12-31 | 21.27% | Rs1.69 Billion ≈ $18.28 Million |
Rs7.94 Billion ≈ $85.91 Million |
-11.18pp |
| 2022-12-31 | 32.45% | Rs3.57 Billion ≈ $38.65 Million |
Rs11.01 Billion ≈ $119.09 Million |
-5.27pp |
| 2021-12-31 | 37.72% | Rs3.37 Billion ≈ $36.46 Million |
Rs8.94 Billion ≈ $96.65 Million |
-5.76pp |
| 2020-12-31 | 43.48% | Rs4.29 Billion ≈ $46.37 Million |
Rs9.86 Billion ≈ $106.65 Million |
-7.40pp |
| 2019-12-31 | 50.88% | Rs5.99 Billion ≈ $64.73 Million |
Rs11.76 Billion ≈ $127.22 Million |
+18.21pp |
| 2018-12-31 | 32.67% | Rs5.75 Billion ≈ $62.17 Million |
Rs17.59 Billion ≈ $190.28 Million |
+25.61pp |
| 2017-12-31 | 7.06% | Rs699.70 Million ≈ $7.57 Million |
Rs9.91 Billion ≈ $107.20 Million |
+3.91pp |
| 2016-12-31 | 3.15% | Rs277.80 Million ≈ $3.00 Million |
Rs8.83 Billion ≈ $95.47 Million |
-2.25pp |
| 2015-12-31 | 5.39% | Rs422.80 Million ≈ $4.57 Million |
Rs7.84 Billion ≈ $84.78 Million |
+2.02pp |
| 2014-12-31 | 3.37% | Rs238.70 Million ≈ $2.58 Million |
Rs7.08 Billion ≈ $76.59 Million |
-0.37pp |
| 2013-12-31 | 3.74% | Rs242.90 Million ≈ $2.63 Million |
Rs6.49 Billion ≈ $70.14 Million |
-0.23pp |
| 2012-12-31 | 3.98% | Rs236.40 Million ≈ $2.56 Million |
Rs5.94 Billion ≈ $64.27 Million |
-17.82pp |
| 2006-12-31 | 21.80% | Rs1.04 Billion ≈ $11.30 Million |
Rs4.79 Billion ≈ $51.84 Million |
+0.55pp |
| 2005-12-31 | 21.25% | Rs823.10 Million ≈ $8.90 Million |
Rs3.87 Billion ≈ $41.90 Million |
+7.70pp |
| 2004-12-31 | 13.54% | Rs442.80 Million ≈ $4.79 Million |
Rs3.27 Billion ≈ $35.36 Million |
+2.75pp |
| 2003-12-31 | 10.79% | Rs300.00 Million ≈ $3.24 Million |
Rs2.78 Billion ≈ $30.07 Million |
-- |
About Procter & Gamble Health Limited
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter … Read more